ArticleVirology journal2026
Major protease inhibitor drug resistance mutations among patients with virological failure on second-line antiretroviral therapy in Zimbabwe: a retrospective cross-sectional study.
Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundVirological failure (VF) on protease inhibitor (PI)-based second-line antiretroviral therapy (ART) remains an important driver of HIV drug resistance (HIVDR) in sub-Saharan Africa. Despite widespread adoption of dolutegravir (DTG)-based first-line ART, many people living with HIV (PLWH) remain on PI-based second-line regimens. Data on major PI drug resistance mutations (DRMs) in Zimbabwe remain limited.
methodsWe conducted a retrospective cross-sectional study of archived plasma specimens from PLWH with VF (viral load (VL) ≥ 1,000 copies/mL) receiving PI-based second-line ART in Zimbabwe between January 2021 and June 2025. HIV-1 protease and reverse transcriptase regions were Sanger-sequenced, and resistance was interpreted using the Stanford HIV Drug Resistance Database. Factors associated with major PI DRMs were evaluated using multivariable logistic regression.
resultsAmong 297 participants, 153 (51.5%, 95% confidence interval [CI] 45.8-57.2%) harboured major PI DRMs. The most frequent mutations were M46I (22.6%), V82A (19.2%), and I54V (17.2%). NRTI- and NNRTI-associated DRMs were present in 70.4% and 79.5% of participants, respectively, while 47.8% exhibited triple-class resistance. Predicted susceptibility to darunavir/ritonavir remained high (78.8%), despite resistance to atazanavir/ritonavir (45.5%) and lopinavir/ritonavir (50.8%). In multivariable analysis, increasing age (adjusted odds ratio [aOR] 1.04, P < 0.001), higher VL (aOR 1.55, P = 0.011) and male sex (aOR 1.59, P = 0.044) were independently associated with major PI DRMs.
conclusionsMajor PI DRMs and multiclass HIVDR were common among PLWH with VF on PI-based second-line ART. Routine VL monitoring and early resistance testing are needed to detect and guide second-line ART failure in Zimbabwe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.